High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Fraunholz, Ingeborg ^a   Rödel, Claus ^a   Distel, Luitpold ^b   Rave Fränk, Marget ^c   Kohler, Daniela ^a   Falk, Stefan ^d   Rödel, Franz ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Pathology Associates   (Germany)

Author keywords

Anal cancer; Concurrent chemoradiotherapy; Molecular marker; Survivin

Indexed keywords

FLUOROURACIL; MITOMYCIN C; SURVIVIN;

ADULT; ANUS CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CORRELATION ANALYSIS; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; RISK FACTORS;

EID: 84862227326     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-88     Document Type: Article

References (39)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921. 10.1038/nm0897-917, 9256286.
2. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010, 430:199-205. 10.1042/BJ20100814, 3198835, 20704571.
3. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70. 10.1038/nrc2293, 18075512.
4. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3:46-54. 10.1038/nrc968, 12509766.
5. Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today 2011, 41:175-182. 10.1007/s00595-010-4390-1, 21264751.
6. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005. 10.1158/1078-0432.CCR-08-0746, 18698017.
7. Weiss C, von Römer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, Sauer R, Rödel C, Rödel F. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2009, 74:1455-1460. 10.1016/j.ijrobp.2008.10.063, 19231102.
8. Rödel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, Schick C, Sauer R, Rödel C. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002, 178:426-435. 10.1007/s00066-002-1003-y, 12240548.
9. Zhang M, Ho A, Hammond EH, Suzuki Y, Bermudez RS, Lee RJ, Pilepich M, Shipley WU, Sandler H, Khor LY, et al. Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int J Radiat Oncol Biol Phys 2009, 73:1033-1042. 10.1016/j.ijrobp.2008.06.1489, 2678565, 18977097.
10. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009, 35:553-562. 10.1016/j.ctrv.2009.05.003, 19559538.
11. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011, 16:485-494. 10.1016/j.drudis.2011.04.001, 21511051.
12. Rödel F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T, Fulda S, Rödel C. The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr Med Chem 2011, 18:191-199. 10.2174/092986711794088362, 21110807.
13. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008, 26:5198-5203. 10.1200/JCO.2008.17.2064, 18824702.
14. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andre V, Kadam S, Burgess M, Slapak C, Olsen AL, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010, 16:6150-6158. 10.1158/1078-0432.CCR-10-1932, 21041181.
15. Allal AS, Waelchli L, Brundler MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 2003, 9:6489-6496.
16. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 2010, 55:1098-1105. 10.1007/s10620-009-0812-6, 19399614.
17. Allal AS, Brundler MA, Gervaz P. Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus. Int J Colorectal Dis 2005, 20:161-164. 10.1007/s00384-004-0651-z, 15688099.
18. Allal AS, Alonso-Pentzke L, Remadi S. Apparent lack of prognostic value of MIB-1 index in anal carcinomas treated by radiotherapy. Br J Cancer 1998, 77:1333-1336. 10.1038/bjc.1998.222, 2150158, 9579842.
19. Indinnimeo M, Cicchini C, Stazi A, Limiti MR, Ghini C, Mingazzini P, Vecchione A. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 2000, 19:471-475.
20. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006, 12:3355-3360. 10.1158/1078-0432.CCR-05-2434, 16740757.
21. Cummings BJ. Metastatic anal cancer: the search for cure. Onkologie 2006, 29:5-6. 10.1159/000090747, 16514247.
22. Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res 2008, 2:10-14. 2630809, 19259318.
23. Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, Cleator S. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer 2010, 103:1858-1869. 10.1038/sj.bjc.6605984, 3008609, 21063399.
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
25. Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, Xu N, Xiao Z. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol 2011, 32:1147-1153. 10.1007/s13277-011-0217-y, 21826474.
26. Bache M, Holzapfel D, Kappler M, Holzhausen HJ, Taubert H, Dunst J, Hansgen G. Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. Gynecol Oncol 2007, 104:139-144. 10.1016/j.ygyno.2006.07.011, 16919715.
27. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P, Ross JS. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004, 12:44-49.
28. Zhang Y, Huang D, Yu G. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas. Acta Otolaryngol 2005, 125:1345-1350. 10.1080/00016480510043963, 16303685.
29. Vallbohmer D, Kuhn E, Warnecke-Eberz U, Brabender J, Hoffmann AC, Metzger R, Baldus SE, Drebber U, Hoelscher AH, Schneider PM. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 2008, 9:681-690. 10.2217/14622416.9.6.681, 18518847.
30. Sprenger T, Rödel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, Wolff HA, Ghadimi BM, Yildirim M, Becker H, et al. Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011, 17:1623-1631. 10.1158/1078-0432.CCR-10-2592, 21118954.
31. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell 2010, 17:53-64. 10.1016/j.ccr.2009.11.021, 2818597, 20129247.
32. Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 2011,
33. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004, 23:7494-7506. 10.1038/sj.onc.1208049, 15326475.
34. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003, 55:1341-1347. 10.1016/S0360-3016(02)04618-7, 12654446.
35. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000, 91:1204-1209. 10.1111/j.1349-7006.2000.tb00906.x, 11092988.
36. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-4887. 10.1158/0008-5472.CAN-04-3028, 15930309.
37. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008, 14:6496-6504. 10.1158/1078-0432.CCR-08-0468, 18927289.
38. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009, 15:3872-3880. 10.1158/1078-0432.CCR-08-1946, 19470738.
39. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011, 68:505-511. 10.1007/s00280-010-1506-7, 21079959.